Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial

Introduction The efficacy of natalizumabwas evaluated in Japanese patients with relapsing-remitting multiple sclerosis(RRMS) in a 24-week, phase 2 bridging study. An open-label, 2-year extension study from this trial was conducted to assess the safety and efficacy of natalizumabtreatment in Japanese patients.